NCT00524940View on ClinicalTrials.gov

Trial to Describe the Safety and Immunogenicity of Fluzone®

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

September 30, 2007

Study Completion Date

December 31, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Inactivated, Split-Virion Influenza Virus

0.5 mL, Intramuscular

Trial Locations (1)

23507

Norfolk

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00524940 - Trial to Describe the Safety and Immunogenicity of Fluzone® | Biotech Hunter | Biotech Hunter